Status:
COMPLETED
Phase II Iressa & Carbo/Gem in NSCLC
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to ge...
Eligibility Criteria
Inclusion
- Advanced Non Small cell Lung Cell Lung cancer
- Never received chemotherapy
- Up and about 50% of waking hours
Exclusion
- Spread of lung cancer to the brain
- Low level of white blood cells
- Radiotherapy within 4 weeks
- Patients were entered to this study, initiated in 2004, before the significance of predictive factors such as smoking history, adenocarcinoma histology and mutation status was described.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00264498
Start Date
October 1 2004
End Date
June 1 2008
Last Update
August 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Montreal, Quebec, Canada